Stocks · News reference

Design Therapeutics Starts Patient Dosing In Its Phase 1 Multiple-Ascending Dose Clinical Study Of DT-818 In Adults With Myotonic Dystrophy Type-1

Jun 30, 2026, 12:06 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 3, 2026, 12:04 PMBenzinga Newsdesk
Design Therapeutics Q2 EPS $(0.32) Beats $(0.34) Estimate
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.34) by 5.88 percent. This is a 5.88 percent increase over losses of $(0.34) per share
Read original at benzinga
DSGN
SEC EDGARAug 3, 2026, 12:03 PMSEC EDGAR
8-K filing — Design Therapeutics, Inc. (DSGN)
Filed: 2026-08-03 AccNo: 0001193125-26-329570 Size: 489 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar
DSGN